What is Wedbush's Forecast for ANRO FY2029 Earnings?

Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Research analysts at Wedbush issued their FY2029 earnings per share (EPS) estimates for Alto Neuroscience in a research note issued to investors on Thursday, March 20th. Wedbush analyst L. Chico expects that the company will earn ($2.88) per share for the year. The consensus estimate for Alto Neuroscience's current full-year earnings is ($2.54) per share.

Separately, William Blair restated an "outperform" rating on shares of Alto Neuroscience in a report on Friday, March 21st. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $16.75.

Alto Neuroscience Trading Down 3.4 %

Alto Neuroscience stock traded down $0.09 during midday trading on Monday, reaching $2.42. The stock had a trading volume of 222,480 shares, compared to its average volume of 358,793. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. The firm has a market cap of $65.13 million and a price-to-earnings ratio of -0.95. Alto Neuroscience has a 52-week low of $2.37 and a 52-week high of $18.31. The company has a fifty day moving average of $3.53 and a 200 day moving average of $5.88.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.09.

Remove Ads

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ANRO. Wellington Management Group LLP increased its holdings in Alto Neuroscience by 27.2% in the fourth quarter. Wellington Management Group LLP now owns 77,146 shares of the company's stock valued at $326,000 after buying an additional 16,510 shares in the last quarter. AWM Investment Company Inc. boosted its position in Alto Neuroscience by 22.9% during the fourth quarter. AWM Investment Company Inc. now owns 687,831 shares of the company's stock worth $2,910,000 after purchasing an additional 128,100 shares in the last quarter. Woodline Partners LP grew its holdings in Alto Neuroscience by 397.6% in the fourth quarter. Woodline Partners LP now owns 621,976 shares of the company's stock valued at $2,631,000 after purchasing an additional 496,976 shares during the period. Vestal Point Capital LP grew its holdings in Alto Neuroscience by 40.8% in the fourth quarter. Vestal Point Capital LP now owns 915,000 shares of the company's stock valued at $3,870,000 after purchasing an additional 265,000 shares during the period. Finally, Two Sigma Investments LP increased its position in shares of Alto Neuroscience by 137.2% in the fourth quarter. Two Sigma Investments LP now owns 30,700 shares of the company's stock valued at $130,000 after buying an additional 17,760 shares in the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.